Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Eton Pharmaceuticals acquires HEMANGEOL rights

PUBLIC · ETONMar 19, 20264 months ago

Acquiring Company

Eton Pharmaceuticals

Acquired Company

Hemangeol

Deer ParkBiotechnologyHealthcareHealth CarePharmaceuticalBiotechnologyHealth Care

Description

Eton Pharmaceuticals has acquired U.S. rights to the orphan drug HEMANGEOL, expected to enhance their sales strategy in pediatric dermatology. This acquisition is aligned with Eton's growth initiatives and will allow them to integrate HEMANGEOL into their existing patient support programs. The commercialization of HEMANGEOL is scheduled for May 1st, further boosting Eton's portfolio of rare disease treatments.

Company Information

Company

Eton Pharmaceuticals

Location

Deer Park, Illinois, United States

About

Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.

Related People

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Eton Pharmaceuticals's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.